Related Experiment Video
Updated: May 23, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
PSMA-based Theranostics in Advanced Non-small Cell Lung Cancer: A Hit or a Miss?
Piyush Aggarwal1, Anupriya Anwariya1, Komalpreet Kaur1
1Departments of Nuclear Medicine.
Abstract:
Prostate-specific membrane antigen (PSMA) overexpression on prostate cancer cells finally led to the FDA approval of the therapeutic use of 177 Lu-PSMA-617 in metastatic castrate-resistant prostate cancer. However, PSMA is also expressed in the neovasculature of other solid tumors, such as lung and renal cancer, making the theranostic potential of 177 Lu-PSMA-617 worth exploring in this setting. Here is such a case of an 83-year-old man with advanced non-small cell lung cancer where the theranostic potential of 177 Lu-PSMA-617 was explored using dosimetric analysis.
Insights
177Lu-PSMA-617 shows theranostic potential beyond prostate cancer. This case explores its use in advanced non-small cell lung cancer, demonstrating its applicability in other solid tumors with PSMA expression.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceuticals
Background:
- Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer, leading to FDA approval of 177Lu-PSMA-617 therapy.
- PSMA is also found in the neovasculature of other solid tumors, including lung and renal cancers.
- This suggests a potential theranostic role for 177Lu-PSMA-617 in these malignancies.
Purpose of the Study:
- To investigate the theranostic potential of 177Lu-PSMA-617 in a patient with advanced non-small cell lung cancer.
- To evaluate the feasibility of using 177Lu-PSMA-617 for both diagnosis and therapy in non-prostate cancers.
Main Methods:
- Case study of an 83-year-old male with advanced non-small cell lung cancer.
- Exploration of 177Lu-PSMA-617 theranostic potential.
- Utilized dosimetric analysis to assess radiation uptake and distribution.
Main Results:
- The study explored the theranostic application of 177Lu-PSMA-617 in a patient with non-small cell lung cancer.
- Dosimetric analysis was performed to evaluate the uptake and dosimetry of the radiopharmaceutical.
Conclusions:
- 177Lu-PSMA-617 demonstrates potential theranostic value in non-small cell lung cancer.
- Further research is warranted to explore PSMA-targeted theranostics in various solid tumors.
